Canadian CANNAINVESTOR Magazine August / September 2017 - Page 137

127

More recently, on August 1st, Scientus Pharma, a next gen R&D biopharm-aceutical company based just outside of Toronto, expects to launch its first cannabis soft gel capsules for treatment of neuropathic pain at the end of 2017, followed by a soft gel for epilepsy and post-traumatic stress disorder by early 2018. Being one of a limited number of Licensed Dealers in Canada authorized to handle and conduct cannabinoid products, Scientus Pharma has the ability to wholesale, buy, process and sell cannabinoid derivatives, from and to Licensed Producers, as well as international markets. As the release states, “not to grow cannabis plants on any large scale,…but to gain access to end customers”, customers executive chairman Har Grover suggests addresses a $1-billion market. Scientus has large-scale 45,000 square foot facility alreadly in place. They have a unique decarboxylation process allowing them to produce consistent extracts and focus on the pharmaceutical methods of delivery, including the soft gel capsules mentioned above, as well as rapid dissolving sublingual tablets, buccal delivery (oral, such as inhalers/puffers), topical creams, and transdermal patches.